
In what could be a pivotal moment for the future of psychedelic medicine, the Food & Drug Administration (FDA) is weighing a decision to approve MDMA-AT, also known as ecstasy or molly, to treat post-traumatic stress disorder. The FDA is expected to make a decision by Aug. 11.The decision will have a huge impact on military veterans who say the psychedelic drug has relieved their PTSD symptoms. Psychiatrists combine their therapy sessions with the psychedelic medicine.“I have not seen a medicine this powerful in a long time,” Dr. Manish Agrawal, the CEO of Sunstone Therapies, told Fox News.MARINE VET TOUTS BENEFITS OF PSYCHEDELIC-ASSISTED PTSD DRUGS AS FDA CONSIDERS MDM …